NewsGlobeNewswire
BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
· Published
Article summary
—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE—
An excerpt from the original article.
Comments —
Loading comments…